Related references
Note: Only part of the references are listed.A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities
Gerjan de Bruin et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Christoph Driessen et al.
HAEMATOLOGICA (2016)
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Christoph Driessen et al.
HAEMATOLOGICA (2016)
Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells
Geetika Chakravarty et al.
BIOCHIMIE (2016)
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Rachid C. Baz et al.
BLOOD (2016)
Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer
Raymond E. Meyn et al.
CLINICAL CANCER RESEARCH (2016)
Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer
Esme J. Hill et al.
CLINICAL CANCER RESEARCH (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
G. P. Soriano et al.
LEUKEMIA (2016)
Multiple Myeloma: Diagnosis and Treatment
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2016)
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
James M. Wilson et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
N. Nikesitch et al.
BLOOD CANCER JOURNAL (2016)
Treatment options for relapsed and refractory multiple myeloma
Ajay K. Nooka et al.
BLOOD (2015)
The role of P-glycoprotein in drug resistance in multiple myeloma
Joseph Abraham et al.
LEUKEMIA & LYMPHOMA (2015)
What do drug transporters really do?
Sanjay K. Nigam
NATURE REVIEWS DRUG DISCOVERY (2015)
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Sara Bringhen et al.
BLOOD (2014)
Quantification of clonal circulating plasma cells in relapsed multiple myeloma
Wilson I. Gonsalves et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
Lenka Kubiczkova et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
Teresa S. Hawley et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Chungyee Leung-Hagesteijn et al.
CANCER CELL (2013)
Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS
Nan Li et al.
NATURE PROTOCOLS (2013)
The resistance mechanisms of proteasome inhibitor bortezomib
Shuqing Lu et al.
BIOMARKER RESEARCH (2013)
Interaction of innovative small molecule drugs used for cancer therapy with drug transporters
K. Mandery et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma
Valdas Peceliunas et al.
LEUKEMIA & LYMPHOMA (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
Peter Walter et al.
SCIENCE (2011)
Nelfinavir, an HIV-1 Protease Inhibitor, Induces Oxidative Stress-Mediated, Caspase-Independent Apoptosis in Leishmania Amastigotes
Pranav Kumar et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Calcium Channel Blocker Verapamil Enhances Endoplasmic Reticulum Stress and Cell Death Induced by Proteasome Inhibition in Myeloma Cells
Silke Meister et al.
NEOPLASIA (2010)
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
D. Gutman et al.
LEUKEMIA (2009)
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells
T. Rueckrich et al.
LEUKEMIA (2009)
Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs
Par Matsson et al.
PHARMACEUTICAL RESEARCH (2009)
HIV drug development: the next 25 years
Charles Flexner
NATURE REVIEWS DRUG DISCOVERY (2007)
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors
Holger Rumpold et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo
JoellJ. Gills et al.
CLINICAL CANCER RESEARCH (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Mitochondrial membrane permeabilization in cell death
Guido Kroemer et al.
PHYSIOLOGICAL REVIEWS (2007)
IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes
Yasunori Nakagawa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells
S Wirths et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
GS Nowakowski et al.
BLOOD (2005)
Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor
JGR Weaver et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats
M Kageyama et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I
C Batandier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mitotracker Green is a P-glycoprotein substrate
LF Marques-Santos et al.
BIOSCIENCE REPORTS (2003)
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
FH Zhan et al.
BLOOD (2002)
Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma
H Schwarzenbach
MEDICAL ONCOLOGY (2002)
Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells
NP Dantuma et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
